Phase 1/early phase trial patients

What to do if patient is on phase 1/early phase trial

Phase 1 information 

Patients may be receiving experimental agents via trials. This is especially true for Phase I trials, but Phase 2 and even Phase 3 trials may involve very new agents that are not fully understood, or where there is little local experience of that type of agent. As a result, patients may experience toxicities that are unusual or unexpected. Therefore, a possible contribution from the experimental agent should always be considered with any new symptoms.  

The oncall oncology registrar (available via Lothian Switchboard) must be made aware of all patients who are unwell and acutely admitted to hospital on an experimental agent. So if in doubt, please let us know. Further advice on management of the patient’s symptoms will be available through the trial protocol (or the drug’s Investigation Brochure (IB)), accessible by the on call oncology team.